<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00141271</url>
  </required_header>
  <id_info>
    <org_study_id>A1281136</org_study_id>
    <nct_id>NCT00141271</nct_id>
  </id_info>
  <brief_title>A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression</brief_title>
  <official_title>A Six-Week, Randomized, Double-Blind, Multicenter, Fixed-Flexible Dose, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral Ziprasidone in Outpatients With Bipolar I Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 6-week trial that evaluates the efficacy and safety of Geodon (ziprasidone) in
      outpatient subjects ages 18 and older with Bipolar Disorder type I, depressed. Subjects are
      required to undergo a washout period of at least 7 days of any prior med.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Montgomery-Asberg Depression Rating Scale (MADRS)Total Score</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Greater Than or Equal to 50 Percent Decrease From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS)Total Score</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Greater Than or Equal to 50 Percent Decrease From Baseline in Hamilton Depression Rating Scale (HAM-D 17) Total Score</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Global Assessment of Functioning (GAF)at Endpoint, Last Observation Carried Forward (LOCF)</measure>
    <time_frame>Baseline, 6 Weeks LOCF</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission as Measured by Montgomery-Asberg Depression Rating Scale (MADRS) Total Score Less Than or Equal to 12</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission as Measured by Hamilton Depression (HAM-D 17) Total Score Less Than or Equal to 7</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hamilton Depression (HAM-D 17) Total Score</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hamilton Anxiety Rating (HAM-A)</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Score of Young Mania Rating Scale (YMRS)</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Assessment of Global Clinical Severity of Symptoms (CGI-S)</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Global Clinical Improvement of Symptoms (CGI -I)</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Score in Hamilton Depression (HAM-D 25)</measure>
    <time_frame>Baseline to 6 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response as Measured by CGI-I Score Less Than or Equal to 2</measure>
    <time_frame>Week 1 through Week 6 (endpoint)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sheehan Disability Scale (SDS) Total Score at Endpoint</measure>
    <time_frame>Baseline to Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life, Enjoyment, and Satisfaction Scale (Q-LES-Q) Total Score at Endpoint</measure>
    <time_frame>Baseline to 6 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bech Melancholia Score</measure>
    <time_frame>Baseline to 6 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Anxiety/Somatizations Factor Total Score</measure>
    <time_frame>Baseline to 6 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Retardation Factor Scores</measure>
    <time_frame>Baseline to 6 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sleep Disturbance Factor Score</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Verbal Memory Trial Performance Total Score at Endpoint</measure>
    <time_frame>Baseline to 6 Weeks LOCF</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Affective Interference Test Immediate Recall List 1 Emotional Words at Endpoint</measure>
    <time_frame>Baseline to 6 Weeks LOCF</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Affective Interference Test Immediate Recall Non-Emotional Words List 1 at Endpoint</measure>
    <time_frame>Baseline to 6 Weeks LOCF</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Affective Interference Test, Immediate Recall, List 2 Emotional Words at Endpoint</measure>
    <time_frame>Baseline to 6 Weeks LOCF</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Affective Interference Test, Immediate Recall, List 2 Non-Emotional Words at Endpoint</measure>
    <time_frame>Baseline to 6 Weeks LOCF</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Affective Interference Test, Immediate Recall, List 3 Emotional Words at Endpoint</measure>
    <time_frame>Baseline to Week 6 LOCF</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Affective Interference Test, Immediate Recall, List 3 Non-Emotional Words at Endpoint</measure>
    <time_frame>Baseline to Week 6 LOCF</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Affective Interference Test, Immediate Recall, Cued-Recall Non-Emotional Words at Endpoint</measure>
    <time_frame>Baseline to 6 Weeks LOCF</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Affective Interference Test, Immediate Recall, Cued-Recall Emotional Words at Endpoint</measure>
    <time_frame>Baseline to 6 Weeks LOCF</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Digit Sequencing Task at Endpoint</measure>
    <time_frame>Baseline to 6 Weeks LOCF</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Token Motor Task at Endpoint</measure>
    <time_frame>Baseline to 6 Weeks LOCF</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Verbal Fluency in Naming Categories at Endpoint</measure>
    <time_frame>Baseline to 6 Weeks LOCF</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Verbal Fluency Controlled Word Association at Endpoint</measure>
    <time_frame>Baseline to 6 Weeks LOCF</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Symbol Coding at Endpoint</measure>
    <time_frame>Baseline to 6 Weeks LOCF</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tower of London Test at Endpoint</measure>
    <time_frame>Baseline to 6 Weeks LOCF</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Affective Interference Test, Delayed Recognition, Emotional Words at Endpoint</measure>
    <time_frame>Baseline to 6 Weeks LOCF</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Affective Interference Test, Delayed Recognition, Emotional Words False Alarms at Endpoint</measure>
    <time_frame>Baseline to 6 Weeks LOCF</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Affective Interference Test, Delayed Recognition, Non-Emotional Words at Endpoint</measure>
    <time_frame>Baseline to Week 6 LOCF</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Affective Interference Test, Delayed Recognition, Non-Emotional Words False Alarms at Endpoint</measure>
    <time_frame>Baseline to Week 6 LOCF</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">536</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>20-40mg BID arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>60-80mg bid arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Geodon (Ziprasidone)</intervention_name>
    <description>Subjects will start at 20mg bid days 1-6, then flexible dosing starting on day 7 between 20-40mg bid (20mg bid or 40mg bid) for the remainder of the 6 week trial</description>
    <arm_group_label>20-40mg BID arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Geodon (Ziprasidone)</intervention_name>
    <description>Subjects will start at 20mg bid days 1-2, then 40mg bid days 3-4, them 60mg bid for days 5-6 then flexible dosing starting on day 7 between 60-80mg bid (60 mg bid or 80mg bid) for the remainder of the 6 week trial</description>
    <arm_group_label>60-80mg bid arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will start on placebo and remain on placebo for the remainder of the 6 week trial</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have a primary diagnosis of Bipolar I Disorder, most recent episode
             depressed, with or without rapid cycling, without psychotic features, as defined in
             Diagnostic and Statistical Manual (of Mental Disorders) - Fourth Edition - Text
             Revision (DSM-IV-TR) (296.5X) and confirmed by a structured Mini International
             Neuropsychiatric Interview (MINI)

        Exclusion Criteria:

          -  Subjects with a DSM-IV TR diagnosis of schizophrenia (295.XX), schizoaffective
             disorder (295.70), schizophreniform disorder (295.40), delusional disorder (297.1), or
             psychotic disorder not otherwise specified (298.9).

          -  Subjects with other DSM-IV TR Axis I or Axis II disorder (in addition to Bipolar I
             disorder) are ineligible if the comorbid condition is clinically unstable, requires
             treatment, or has been a primary focus of treatment within the 6 month period prior to
             screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dana Point</city>
        <state>California</state>
        <zip>92629</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ft, Lauderdale</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Schaumburg</city>
        <state>Illinois</state>
        <zip>60194</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Greenwood</city>
        <state>Indiana</state>
        <zip>46143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Prarie Village</city>
        <state>Kansas</state>
        <zip>66206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Clementon</city>
        <state>New Jersey</state>
        <zip>08021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mayfield Village</city>
        <state>Ohio</state>
        <zip>44143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19149</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203-1515</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>DeSoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0188</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <zip>75080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284-7792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <zip>76309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>West Allis</city>
        <state>Wisconsin</state>
        <zip>53227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1281136&amp;StudyName=A%20Six-Week%20Study%20Evaluating%20The%20Efficacy%20And%20Safety%20Of%20Geodon%20In%20Patients%20With%20A%20Diagnosis%20Of%20Bipolar%20I%20Depression</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2005</study_first_submitted>
  <study_first_submitted_qc>August 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2005</study_first_posted>
  <results_first_submitted>February 24, 2009</results_first_submitted>
  <results_first_submitted_qc>February 24, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 24, 2009</results_first_posted>
  <last_update_submitted>April 3, 2009</last_update_submitted>
  <last_update_submitted_qc>April 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer Inc</organization>
  </responsible_party>
  <keyword>Bipolar I Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>56 centers in the US</recruitment_details>
      <pre_assignment_details>7-day washout:psychotropic drugs &amp; lithium. 4-week washout: monoamine oxidase inhibitors, fluoxetine alone or in combination with olanzapine. Depot neuroleptic Discontinued (DC'd) 6 mo prior to entry. 536 subjects enrolled: 504 assigned to drug; 32 not assigned:18 lost to follow up, 5 DC'd study, 9 didn't take/receive study drug for other reasons.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>120-160mg Ziprasidone</title>
          <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
        </group>
        <group group_id="P2">
          <title>40-80 mg Ziprasidone</title>
          <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Subjects were assigned to placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="171"/>
                <participants group_id="P2" count="165"/>
                <participants group_id="P3" count="168"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="57"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Laboratory Abnormality</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>120-160mg Ziprasidone</title>
          <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
        </group>
        <group group_id="B2">
          <title>40-80 mg Ziprasidone</title>
          <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Subjects were assigned to placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="171"/>
            <count group_id="B2" value="165"/>
            <count group_id="B3" value="168"/>
            <count group_id="B4" value="504"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.4" spread="12.9"/>
                    <measurement group_id="B2" value="40.0" spread="11.4"/>
                    <measurement group_id="B3" value="39.3" spread="11.2"/>
                    <measurement group_id="B4" value="39.9" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="92"/>
                    <measurement group_id="B4" value="284.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="220.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Montgomery-Asberg Depression Rating Scale (MADRS)Total Score</title>
        <description>Change is observed value at each visit minus baseline value. Overall is average response of Weeks 1 - 6. MADRS is 10-item instrument measuring depression; scale 0(Normal) and 6(most abnormal). Total possible score is 0 - 60.</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <population>Intent to treat (ITT) population observed cases</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Montgomery-Asberg Depression Rating Scale (MADRS)Total Score</title>
          <description>Change is observed value at each visit minus baseline value. Overall is average response of Weeks 1 - 6. MADRS is 10-item instrument measuring depression; scale 0(Normal) and 6(most abnormal). Total possible score is 0 - 60.</description>
          <population>Intent to treat (ITT) population observed cases</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=161, 153, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.07" spread="0.62"/>
                    <measurement group_id="O2" value="-7.66" spread="0.73"/>
                    <measurement group_id="O3" value="-5.75" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=135, 142, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.12" spread="0.79"/>
                    <measurement group_id="O2" value="-10.20" spread="0.82"/>
                    <measurement group_id="O3" value="-9.47" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=120, 131, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.61" spread="0.88"/>
                    <measurement group_id="O2" value="-12.93" spread="0.85"/>
                    <measurement group_id="O3" value="-11.37" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=106, 126, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.54" spread="0.88"/>
                    <measurement group_id="O2" value="-13.87" spread="0.91"/>
                    <measurement group_id="O3" value="-12.49" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (n=99, 115, 123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.25" spread="0.94"/>
                    <measurement group_id="O2" value="-14.53" spread="0.90"/>
                    <measurement group_id="O3" value="-12.99" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=95, 107, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.81" spread="1.02"/>
                    <measurement group_id="O2" value="-14.77" spread="0.97"/>
                    <measurement group_id="O3" value="-13.25" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall (n=166, 158, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.40" spread="0.73"/>
                    <measurement group_id="O2" value="-12.33" spread="0.74"/>
                    <measurement group_id="O3" value="-10.89" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6409</p_value>
            <p_value_desc>Hochbergs adjustment was used for multiple comparisons adjustment</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0140</p_value>
            <p_value_desc>Hochbergs adjustment used for multiple comparisons adjustment</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4840</p_value>
            <p_value_desc>Hochbergs adjustment used for multiple comparisons adjustment</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4444</p_value>
            <p_value_desc>Hochbergs adjustment used for multiple comparisons adjustment</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8129</p_value>
            <p_value_desc>Hochbergs adjustment used for multiple comparisons adjustment</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1105</p_value>
            <p_value_desc>Hochbergs adjustment used for multiple comparisons adjustment</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9582</p_value>
            <p_value_desc>Hochbergs adjustment used for multiple comparisons adjustment</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1893</p_value>
            <p_value_desc>Hochbergs adjustment used for multiple comparisons adjustment</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2924</p_value>
            <p_value_desc>Hochbergs adjustment used for multiple comparisons adjustment</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Hochbergs adjustment used for multiple comparisons adjustment</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1897</p_value>
            <p_value_desc>Hochbergs adjustment used for multiple comparisons adjustment</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6 An estimated sample size of 180 was needed per treatment arm in order to achieve 85% power to detect a treatment difference of 3.5 in the mean change from baseline to Week 6 in MADRS total score with a two-sided t-test at the 0.05 significance level. The common standard deviation was estimated as 11.0.
The null hypotheses for the primary parameter is equality of mean change from baseline to Week 6 in MADRS total score between ziprasidone and placebo groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6608</p_value>
            <p_value_desc>Hochbergs adjustment used for multiple comparisons adjustment</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6 An estimated sample size of 180 was needed per treatment arm in order to achieve 85% power to detect a treatment difference of 3.5 in the mean change from baseline to Week 6 in MADRS total score with a two-sided t-test at the 0.05 significance level. The common standard deviation was estimated as 11.0.
The null hypotheses for the primary parameter is equality of mean change from baseline to Week 6 in MADRS total score between ziprasidone and placebo groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2148</p_value>
            <p_value_desc>Hochbergs adjustment used for multiple comparisons adjustment</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Overall</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5290</p_value>
            <p_value_desc>Hochbergs adjustment used for multiple comparisons adjustment</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Overall</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0811</p_value>
            <p_value_desc>Hochbergs adjustment used for multiple comparisons adjustment</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Greater Than or Equal to 50 Percent Decrease From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS)Total Score</title>
        <description>Participants with MADRS Total Score greater or equal to 50 percent decrease from baseline responded yes; others responded no. Endpoint is last observation carried forward (LOCF) among Week 1 - Week 6; MADRS is 10-item instrument measuring depression; scale range 0(Normal) and 6 (most abnormal). Total possible score is 0 - 60</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <population>Intent to treat (ITT) population observed cases.
Not all subjects answered at each Week</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Response Greater Than or Equal to 50 Percent Decrease From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS)Total Score</title>
          <description>Participants with MADRS Total Score greater or equal to 50 percent decrease from baseline responded yes; others responded no. Endpoint is last observation carried forward (LOCF) among Week 1 - Week 6; MADRS is 10-item instrument measuring depression; scale range 0(Normal) and 6 (most abnormal). Total possible score is 0 - 60</description>
          <population>Intent to treat (ITT) population observed cases.
Not all subjects answered at each Week</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="121"/>
                    <measurement group_id="O3" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 : Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2287</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4734</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7401</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7904</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5274</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1059</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8871</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6939</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1044</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3132</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6978</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3228</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6432</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5989</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Greater Than or Equal to 50 Percent Decrease From Baseline in Hamilton Depression Rating Scale (HAM-D 17) Total Score</title>
        <description>Participants with greater than or equal to 50 percent decrease from baseline in HAMD-17 total score responded yes; others responded no. Endpoint is LOCF endpoint among Week 1 - 6; Total score is first 17 items of HAM-D 25: measures range of depressive symptoms; scale 0-2 or 0-4 with higher scores being more severe. Total possible score 0 - 52.</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <population>Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6
Not all subjects answered each Week.</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Response Greater Than or Equal to 50 Percent Decrease From Baseline in Hamilton Depression Rating Scale (HAM-D 17) Total Score</title>
          <description>Participants with greater than or equal to 50 percent decrease from baseline in HAMD-17 total score responded yes; others responded no. Endpoint is LOCF endpoint among Week 1 - 6; Total score is first 17 items of HAM-D 25: measures range of depressive symptoms; scale 0-2 or 0-4 with higher scores being more severe. Total possible score 0 - 52.</description>
          <population>Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6
Not all subjects answered each Week.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 3: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8921</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4350</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5620</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6959</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7865</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7564</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Global Assessment of Functioning (GAF)at Endpoint, Last Observation Carried Forward (LOCF)</title>
        <description>Change is observed value at endpoint minus baseline value. Endpoint is Last Observation Carried Forward (LOCF) endpoint among Week 1 - 6; GAF is used to assess global psychological, social, &amp; occupational functioning; 100=normal and 0=greatest abnormality</description>
        <time_frame>Baseline, 6 Weeks LOCF</time_frame>
        <population>Intent to treat (ITT) population observed cases, Last Observation Carried Forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Global Assessment of Functioning (GAF)at Endpoint, Last Observation Carried Forward (LOCF)</title>
          <description>Change is observed value at endpoint minus baseline value. Endpoint is Last Observation Carried Forward (LOCF) endpoint among Week 1 - 6; GAF is used to assess global psychological, social, &amp; occupational functioning; 100=normal and 0=greatest abnormality</description>
          <population>Intent to treat (ITT) population observed cases, Last Observation Carried Forward (LOCF).</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.11" spread="1.38"/>
                    <measurement group_id="O2" value="11.72" spread="1.37"/>
                    <measurement group_id="O3" value="11.19" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4327</p_value>
            <p_value_desc>For all efficacy analyses, no multiple comparisons adjustments were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7041</p_value>
            <p_value_desc>For all efficacy analyses, no multiple comparisons adjustments were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Remission as Measured by Montgomery-Asberg Depression Rating Scale (MADRS) Total Score Less Than or Equal to 12</title>
        <description>Response was Yes if MADRS Total Score was less than, equal to 12, if not, response was no. Endpoint is LOCF endpoint among Week 1 through 6; MADRS is 10-item instrument measuring depression; scale range 0(Normal) and 6(most abnormal)</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <population>ITT Observed Cases.Endpoint is LOCF endpoint among Week 1 through Week 6;
Not all subjects answered each week.</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Remission as Measured by Montgomery-Asberg Depression Rating Scale (MADRS) Total Score Less Than or Equal to 12</title>
          <description>Response was Yes if MADRS Total Score was less than, equal to 12, if not, response was no. Endpoint is LOCF endpoint among Week 1 through 6; MADRS is 10-item instrument measuring depression; scale range 0(Normal) and 6(most abnormal)</description>
          <population>ITT Observed Cases.Endpoint is LOCF endpoint among Week 1 through Week 6;
Not all subjects answered each week.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1; Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1; No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="126"/>
                    <measurement group_id="O3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2; Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2; No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="101"/>
                    <measurement group_id="O3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3; Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3; No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4; Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4; No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5; Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5; No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6; Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6; No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint; Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint; No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2076</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7449</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4399</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7107</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4765</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2564</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8063</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9855</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0599</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7364</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3048</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5139</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9356</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9428</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Remission as Measured by Hamilton Depression (HAM-D 17) Total Score Less Than or Equal to 7</title>
        <description>Response was yes when HAM-D 17 total score was less than or equal to 7 , if not, response was no. Endpoint is LOCF endpoint among Week 1 through Week 6. Total score is first 17 items of the HAM-D 25,which measures the range of depressive symptoms; scale 0-2 or 0-4 with higher scores being more severe. Total possible score 0 - 52.</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <population>ITT Observed Cases.Endpoint is LOCF endpoint among Week 1 through Week 6
Not all subjects answered each week.</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Remission as Measured by Hamilton Depression (HAM-D 17) Total Score Less Than or Equal to 7</title>
          <description>Response was yes when HAM-D 17 total score was less than or equal to 7 , if not, response was no. Endpoint is LOCF endpoint among Week 1 through Week 6. Total score is first 17 items of the HAM-D 25,which measures the range of depressive symptoms; scale 0-2 or 0-4 with higher scores being more severe. Total possible score 0 - 52.</description>
          <population>ITT Observed Cases.Endpoint is LOCF endpoint among Week 1 through Week 6
Not all subjects answered each week.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 3; Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3; No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="119"/>
                    <measurement group_id="O3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6; Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6; No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="106"/>
                    <measurement group_id="O3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3888</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3122</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3323</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8781</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9485</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7331</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hamilton Depression (HAM-D 17) Total Score</title>
        <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. Total score is first 17 items of the HAM-D 25, which measures the range of depressive symptoms patient currently experiencing; scale 0-2 or 0-4; 0=absent or not depressed, 2 or 4=most severe or extreme. Total possible score 0 - 52.</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <population>ITT Population Observed Cases. Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hamilton Depression (HAM-D 17) Total Score</title>
          <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. Total score is first 17 items of the HAM-D 25, which measures the range of depressive symptoms patient currently experiencing; scale 0-2 or 0-4; 0=absent or not depressed, 2 or 4=most severe or extreme. Total possible score 0 - 52.</description>
          <population>ITT Population Observed Cases. Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 3 (n= 147, 149, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.56" spread="0.82"/>
                    <measurement group_id="O2" value="-10.58" spread="0.81"/>
                    <measurement group_id="O3" value="-10.13" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n= 104,117,125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.37" spread="1.12"/>
                    <measurement group_id="O2" value="-12.82" spread="1.06"/>
                    <measurement group_id="O3" value="-11.30" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (n= 151,150,153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.48" spread="0.95"/>
                    <measurement group_id="O2" value="-11.48" spread="0.95"/>
                    <measurement group_id="O3" value="-10.60" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4869</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5813</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3303</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1546</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8982</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3586</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hamilton Anxiety Rating (HAM-A)</title>
        <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. HAM-A is a 14-item scale: rates intensity of psychic anxiety and somatic anxiety on a 5-point severity scale (range: 0=not present to 4=very severe). Total possible score is 0 - 56.</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <population>ITT population Observed Cases. Endpoint is LOCF endpoint among Week 1 through Week 6</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hamilton Anxiety Rating (HAM-A)</title>
          <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. HAM-A is a 14-item scale: rates intensity of psychic anxiety and somatic anxiety on a 5-point severity scale (range: 0=not present to 4=very severe). Total possible score is 0 - 56.</description>
          <population>ITT population Observed Cases. Endpoint is LOCF endpoint among Week 1 through Week 6</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 3 (n= 147, 148, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.54" spread="0.74"/>
                    <measurement group_id="O2" value="-6.46" spread="0.74"/>
                    <measurement group_id="O3" value="-6.79" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n= 104, 117, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.63" spread="0.94"/>
                    <measurement group_id="O2" value="-7.46" spread="0.89"/>
                    <measurement group_id="O3" value="-6.73" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (n= 151, 150, 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.40" spread="0.81"/>
                    <measurement group_id="O2" value="-6.75" spread="0.81"/>
                    <measurement group_id="O3" value="-6.82" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0896</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6534</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3270</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4099</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6104</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9359</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Score of Young Mania Rating Scale (YMRS)</title>
        <description>Change is observed value at each visit minus baseline value. Overall is average response of Weeks 1 - 6. YMRS: 11 item instrument with scale 0 to 4 for 7 items and 0 to 8 for 4 items; 0=normal; 4 or 8=most abnormal. Total possible score is 0 - 60.</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Score of Young Mania Rating Scale (YMRS)</title>
          <description>Change is observed value at each visit minus baseline value. Overall is average response of Weeks 1 - 6. YMRS: 11 item instrument with scale 0 to 4 for 7 items and 0 to 8 for 4 items; 0=normal; 4 or 8=most abnormal. Total possible score is 0 - 60.</description>
          <population>ITT Population</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n = 140,131, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.34"/>
                    <measurement group_id="O2" value="0.64" spread="0.41"/>
                    <measurement group_id="O3" value="-0.08" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n = 114,124,123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.38"/>
                    <measurement group_id="O2" value="0.64" spread="0.41"/>
                    <measurement group_id="O3" value="0.51" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n = 120, 130, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.44"/>
                    <measurement group_id="O2" value="0.11" spread="0.39"/>
                    <measurement group_id="O3" value="0.05" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n = 93, 116, 116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.43"/>
                    <measurement group_id="O2" value="0.19" spread="0.49"/>
                    <measurement group_id="O3" value="-0.73" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (n = 87, 105, 109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.89" spread="0.43"/>
                    <measurement group_id="O2" value="-0.82" spread="0.43"/>
                    <measurement group_id="O3" value="-0.28" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n = 95, 107, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="0.42"/>
                    <measurement group_id="O2" value="-0.03" spread="0.50"/>
                    <measurement group_id="O3" value="-1.00" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall (n = 161, 158, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.33"/>
                    <measurement group_id="O2" value="0.12" spread="0.36"/>
                    <measurement group_id="O3" value="-0.26" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6924</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0800</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4238</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7714</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8731</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8926</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2072</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1042</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2695</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3245</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7791</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0999</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Overall</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9543</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Overall</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3153</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Assessment of Global Clinical Severity of Symptoms (CGI-S)</title>
        <description>Change is observed value at each visit minus baseline value. Overall is average response of Weeks 1 - 6. CGI-S measures severity of patient's mental illness. Scale range: 0 = not assessed, 1 = normal, 7 = among most extremely ill</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <population>ITT population Observed Cases</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Assessment of Global Clinical Severity of Symptoms (CGI-S)</title>
          <description>Change is observed value at each visit minus baseline value. Overall is average response of Weeks 1 - 6. CGI-S measures severity of patient's mental illness. Scale range: 0 = not assessed, 1 = normal, 7 = among most extremely ill</description>
          <population>ITT population Observed Cases</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=161, 152, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.08"/>
                    <measurement group_id="O2" value="-0.47" spread="0.07"/>
                    <measurement group_id="O3" value="-0.42" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=133, 142, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.84" spread="0.09"/>
                    <measurement group_id="O2" value="-0.82" spread="0.09"/>
                    <measurement group_id="O3" value="-0.75" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=119, 131, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.90" spread="0.11"/>
                    <measurement group_id="O2" value="-1.15" spread="0.10"/>
                    <measurement group_id="O3" value="-0.93" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=105, 126, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.14" spread="0.11"/>
                    <measurement group_id="O2" value="-1.23" spread="0.11"/>
                    <measurement group_id="O3" value="-1.14" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (n=98, 115, 123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.33" spread="0.11"/>
                    <measurement group_id="O2" value="-1.35" spread="0.12"/>
                    <measurement group_id="O3" value="-1.23" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=94, 107, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.38" spread="0.12"/>
                    <measurement group_id="O2" value="-1.38" spread="0.12"/>
                    <measurement group_id="O3" value="-1.35" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall (n=165, 158, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.02" spread="0.09"/>
                    <measurement group_id="O2" value="-1.07" spread="0.09"/>
                    <measurement group_id="O3" value="-0.97" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2878</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4481</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4099</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5093</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8048</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0552</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9795</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5073</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4882</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3967</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8276</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8502</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Overall</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6343</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Overall</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3082</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Global Clinical Improvement of Symptoms (CGI -I)</title>
        <description>Change is observed value at each visit minus baseline value. Overall is average response of Weeks 1 - 6. CGI-I is an instrument for Global assessment of improvement in patient's condition. Scale range: 0=not assessed, 1=very much improved, 7=very much worse</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <population>ITT population Observed Cases</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Global Clinical Improvement of Symptoms (CGI -I)</title>
          <description>Change is observed value at each visit minus baseline value. Overall is average response of Weeks 1 - 6. CGI-I is an instrument for Global assessment of improvement in patient's condition. Scale range: 0=not assessed, 1=very much improved, 7=very much worse</description>
          <population>ITT population Observed Cases</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=162, 152, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.34" spread="0.09"/>
                    <measurement group_id="O2" value="3.17" spread="0.09"/>
                    <measurement group_id="O3" value="3.38" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=134, 142, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.86" spread="0.11"/>
                    <measurement group_id="O2" value="2.82" spread="0.10"/>
                    <measurement group_id="O3" value="3.01" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=120,131,137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.90" spread="0.13"/>
                    <measurement group_id="O2" value="2.62" spread="0.11"/>
                    <measurement group_id="O3" value="2.83" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=106,126,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.54" spread="0.11"/>
                    <measurement group_id="O2" value="2.53" spread="0.11"/>
                    <measurement group_id="O3" value="2.55" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (n=99, 115, 123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.47" spread="0.12"/>
                    <measurement group_id="O2" value="2.48" spread="0.12"/>
                    <measurement group_id="O3" value="2.59" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=95,107, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.49" spread="0.13"/>
                    <measurement group_id="O2" value="2.43" spread="0.13"/>
                    <measurement group_id="O3" value="2.52" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall (n=166, 158, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.77" spread="0.10"/>
                    <measurement group_id="O2" value="2.67" spread="0.09"/>
                    <measurement group_id="O3" value="2.81" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6932</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0287</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2128</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1118</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6144</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0899</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8819</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8374</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3925</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4182</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8586</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5490</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Overall</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6292</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Overall</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1473</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Fixed categorical: treatment, rapid cycling, center, visit, prior hosp &amp; treatment-by-visit interaction &amp; fixed continuous effect of baseline value</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Score in Hamilton Depression (HAM-D 25)</title>
        <description>Change: observed value at each visit minus baseline value. Endpoint is Last Observation Carried Forward (LOCF) endpoint among Week 1 through Week 6. HAM-D 25: measures the range of depressive symptoms experienced. 25 Items with Scale range:0-2 or 0-4; 0=absent or not depressed, 2 or 4=most severe or extreme.Total possible score is 0 - 72.</description>
        <time_frame>Baseline to 6 Weeks</time_frame>
        <population>ITT Population Observed Cases. Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Score in Hamilton Depression (HAM-D 25)</title>
          <description>Change: observed value at each visit minus baseline value. Endpoint is Last Observation Carried Forward (LOCF) endpoint among Week 1 through Week 6. HAM-D 25: measures the range of depressive symptoms experienced. 25 Items with Scale range:0-2 or 0-4; 0=absent or not depressed, 2 or 4=most severe or extreme.Total possible score is 0 - 72.</description>
          <population>ITT Population Observed Cases. Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 3 (n= 147, 149, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.02" spread="0.98"/>
                    <measurement group_id="O2" value="-12.16" spread="0.97"/>
                    <measurement group_id="O3" value="-12.25" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n= 104, 117, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.59" spread="1.32"/>
                    <measurement group_id="O2" value="-15.08" spread="1.25"/>
                    <measurement group_id="O3" value="-13.74" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (n= 151, 150, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.25" spread="1.11"/>
                    <measurement group_id="O2" value="-13.36" spread="1.11"/>
                    <measurement group_id="O3" value="-12.78" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2058</p_value>
            <p_value_desc>For all efficacy analyses, no multiple comparisons adjustments were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9254</p_value>
            <p_value_desc>For all efficacy analyses, no multiple comparisons adjustments were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5071</p_value>
            <p_value_desc>For all efficacy analyses, no multiple comparisons adjustments were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2858</p_value>
            <p_value_desc>For all efficacy analyses, no multiple comparisons adjustments were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6298</p_value>
            <p_value_desc>For all efficacy analyses, no multiple comparisons adjustments were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6034</p_value>
            <p_value_desc>For all efficacy analyses, no multiple comparisons adjustments were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response as Measured by CGI-I Score Less Than or Equal to 2</title>
        <description>Response each week was yes if CGI-I score less than or equal to 2 (much or very much improved), if not, response was no; Endpoint is LOCF endpoint among Week 1 through Week 6. CGI-I is a Global assessment of improvement in patient's condition. Scale range: 0=not assessed, 1=very much improved, 7=very much worse</description>
        <time_frame>Week 1 through Week 6 (endpoint)</time_frame>
        <population>ITT Population Observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6.
Not all subjects answered each week.</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Response as Measured by CGI-I Score Less Than or Equal to 2</title>
          <description>Response each week was yes if CGI-I score less than or equal to 2 (much or very much improved), if not, response was no; Endpoint is LOCF endpoint among Week 1 through Week 6. CGI-I is a Global assessment of improvement in patient's condition. Scale range: 0=not assessed, 1=very much improved, 7=very much worse</description>
          <population>ITT Population Observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6.
Not all subjects answered each week.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1; Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1; No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="118"/>
                    <measurement group_id="O3" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2; Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2; No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3; Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3; No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4; Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4; No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5; Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5; No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6; Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6; No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint; Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint; No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1454</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2672</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2614</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2143</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6997</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0128</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1144</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1483</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0674</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2900</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5482</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0303</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6143</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3385</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by study center and rapid cycling strata was used to compare remission and response rates between ziprasidone and placebo groups</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sheehan Disability Scale (SDS) Total Score at Endpoint</title>
        <description>Observed value each visit minus baseline value. Endpoint is LOCF Week 1 through Week 6. SDS: patient rated measure of disability and impairment in 3 items: work/school, social life, family life/home responsibilities:0(no disruption)- 10(extreme disruption). Total possible is 30.</description>
        <time_frame>Baseline to Week 6</time_frame>
        <population>ITT Population Observed cases. Endpoint is LOCF endpoint among Week 1 - 6; n= 128, 126, 128; number of subjects who responded to the scale.</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sheehan Disability Scale (SDS) Total Score at Endpoint</title>
          <description>Observed value each visit minus baseline value. Endpoint is LOCF Week 1 through Week 6. SDS: patient rated measure of disability and impairment in 3 items: work/school, social life, family life/home responsibilities:0(no disruption)- 10(extreme disruption). Total possible is 30.</description>
          <population>ITT Population Observed cases. Endpoint is LOCF endpoint among Week 1 - 6; n= 128, 126, 128; number of subjects who responded to the scale.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.78" spread="1.01"/>
                    <measurement group_id="O2" value="-5.43" spread="1.02"/>
                    <measurement group_id="O3" value="-6.79" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3299</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1915</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life, Enjoyment, and Satisfaction Scale (Q-LES-Q) Total Score at Endpoint</title>
        <description>Change is observed value at each visit minus baseline value. LOCF endpoint among Week 1 through Week 6. Q-LES-Q: 16-item instrument for patients assessment of his/her quality of life; overall level of satisfaction scale 1=very poor to 5=Very good (1 item re medication can be blank). Total possible score 15 - 80</description>
        <time_frame>Baseline to 6 Weeks</time_frame>
        <population>ITT Population Observed Cases.n= 142, 137, 139; number of subjects who responded to the scale. Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life, Enjoyment, and Satisfaction Scale (Q-LES-Q) Total Score at Endpoint</title>
          <description>Change is observed value at each visit minus baseline value. LOCF endpoint among Week 1 through Week 6. Q-LES-Q: 16-item instrument for patients assessment of his/her quality of life; overall level of satisfaction scale 1=very poor to 5=Very good (1 item re medication can be blank). Total possible score 15 - 80</description>
          <population>ITT Population Observed Cases.n= 142, 137, 139; number of subjects who responded to the scale. Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.02"/>
                    <measurement group_id="O2" value="0.09" spread="0.02"/>
                    <measurement group_id="O3" value="0.09" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5407</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6079</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Bech Melancholia Score</title>
        <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. Bech Melancholia is the sum of Scores on 6 Items pertaining to melancholia within Hamilton Depression Rating Scale (HAM-D). Scale 0 to 4, higher scores reflecting greater severity;Total possible 0 - 24.</description>
        <time_frame>Baseline to 6 Weeks</time_frame>
        <population>ITT Population Observed cases</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bech Melancholia Score</title>
          <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. Bech Melancholia is the sum of Scores on 6 Items pertaining to melancholia within Hamilton Depression Rating Scale (HAM-D). Scale 0 to 4, higher scores reflecting greater severity;Total possible 0 - 24.</description>
          <population>ITT Population Observed cases</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 3 (n = 147, 149, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.12" spread="0.47"/>
                    <measurement group_id="O2" value="-5.61" spread="0.47"/>
                    <measurement group_id="O3" value="-5.22" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n = 104, 117, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.91" spread="0.65"/>
                    <measurement group_id="O2" value="-6.93" spread="0.62"/>
                    <measurement group_id="O3" value="-6.23" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (n =151, 150, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.85" spread="0.54"/>
                    <measurement group_id="O2" value="-6.23" spread="0.54"/>
                    <measurement group_id="O3" value="-5.70" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8464</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4023</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2870</p_value>
            <p_value_desc>For all efficacy analyses, no multiple comparisons adjustments were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2537</p_value>
            <p_value_desc>For all efficacy analyses, no multiple comparisons adjustments were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7909</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3308</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Anxiety/Somatizations Factor Total Score</title>
        <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This instrument = sum of Scores on 6 Items measuring anxiety/somatization within Hamilton Depression Rating Scale (HAM-D). Scale range is 0 to 4, higher scores reflecting greater severity. Total possible 0 - 24.</description>
        <time_frame>Baseline to 6 Weeks</time_frame>
        <population>ITT Population Observed Cases</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Anxiety/Somatizations Factor Total Score</title>
          <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This instrument = sum of Scores on 6 Items measuring anxiety/somatization within Hamilton Depression Rating Scale (HAM-D). Scale range is 0 to 4, higher scores reflecting greater severity. Total possible 0 - 24.</description>
          <population>ITT Population Observed Cases</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 3 (n = 147,149,148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.69" spread="0.30"/>
                    <measurement group_id="O2" value="-2.92" spread="0.30"/>
                    <measurement group_id="O3" value="-2.98" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n = 104,117,125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.67" spread="0.40"/>
                    <measurement group_id="O2" value="-3.88" spread="0.38"/>
                    <measurement group_id="O3" value="-3.62" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (n = 151,150,153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.04" spread="0.34"/>
                    <measurement group_id="O2" value="-3.39" spread="0.34"/>
                    <measurement group_id="O3" value="-3.32" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3355</p_value>
            <p_value_desc>For all efficacy analyses, no multiple comparisons adjustments were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8447</p_value>
            <p_value_desc>For all efficacy analyses, no multiple comparisons adjustments were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8959</p_value>
            <p_value_desc>For all efficacy analyses, no multiple comparisons adjustments were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4826</p_value>
            <p_value_desc>For all efficacy analyses, no multiple comparisons adjustments were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4178</p_value>
            <p_value_desc>For all efficacy analyses, no multiple comparisons adjustments were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8277</p_value>
            <p_value_desc>For all efficacy analyses, no multiple comparisons adjustments were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Retardation Factor Scores</title>
        <description>Change is observed value at each visit minus baseline value. This instrument = sum of Scores of 4 items on retardation within Hamilton Depression Rating Scale (HAM-D). Scale range is 0 to 4 with higher scores reflecting greater severity. Total possible is 0 - 16.</description>
        <time_frame>Baseline to 6 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Retardation Factor Scores</title>
          <description>Change is observed value at each visit minus baseline value. This instrument = sum of Scores of 4 items on retardation within Hamilton Depression Rating Scale (HAM-D). Scale range is 0 to 4 with higher scores reflecting greater severity. Total possible is 0 - 16.</description>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 3 (n = 147,149,148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.50" spread="0.32"/>
                    <measurement group_id="O2" value="-3.64" spread="0.32"/>
                    <measurement group_id="O3" value="-3.59" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n = 104,117,125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.44" spread="0.42"/>
                    <measurement group_id="O2" value="-4.40" spread="0.40"/>
                    <measurement group_id="O3" value="-3.79" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (n = 151,150,153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.89" spread="0.35"/>
                    <measurement group_id="O2" value="-3.99" spread="0.35"/>
                    <measurement group_id="O3" value="-3.62" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7758</p_value>
            <p_value_desc>For all efficacy analyses, no multiple comparisons adjustments were made.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8737</p_value>
            <p_value_desc>For all efficacy analyses, no multiple comparisons adjustments were made.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1151</p_value>
            <p_value_desc>For all efficacy analyses, no multiple comparisons adjustments were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1290</p_value>
            <p_value_desc>For all efficacy analyses, no multiple comparisons adjustments were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4432</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2988</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sleep Disturbance Factor Score</title>
        <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This instrument = sum of Scores of 3 items on sleep disturbance within Hamilton Depression Rating Scale (HAM-D). Scale range 0 to 4 with higher scores reflecting greater severity. Total possible is 0 - 12.</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <population>ITT Population Observed cases</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sleep Disturbance Factor Score</title>
          <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This instrument = sum of Scores of 3 items on sleep disturbance within Hamilton Depression Rating Scale (HAM-D). Scale range 0 to 4 with higher scores reflecting greater severity. Total possible is 0 - 12.</description>
          <population>ITT Population Observed cases</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 3 (n = 147, 149, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.92" spread="0.24"/>
                    <measurement group_id="O2" value="-2.07" spread="0.23"/>
                    <measurement group_id="O3" value="-1.96" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n = 104, 117, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.20" spread="0.30"/>
                    <measurement group_id="O2" value="-2.19" spread="0.28"/>
                    <measurement group_id="O3" value="-2.06" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (n = 151, 150 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.90" spread="0.24"/>
                    <measurement group_id="O2" value="-1.98" spread="0.24"/>
                    <measurement group_id="O3" value="-1.96" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8598</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6513</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6272</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6467</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8049</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9411</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Verbal Memory Trial Performance Total Score at Endpoint</title>
        <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This test is part of Brief Assessment of Cognition and measures recall of 15 words repeated 5 times. Range 0-75 words, higher number reflects better recall.</description>
        <time_frame>Baseline to 6 Weeks LOCF</time_frame>
        <population>Intent to Treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Verbal Memory Trial Performance Total Score at Endpoint</title>
          <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This test is part of Brief Assessment of Cognition and measures recall of 15 words repeated 5 times. Range 0-75 words, higher number reflects better recall.</description>
          <population>Intent to Treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
          <units>words</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="0.97"/>
                    <measurement group_id="O2" value="0.85" spread="0.96"/>
                    <measurement group_id="O3" value="1.22" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9260</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7100</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Affective Interference Test Immediate Recall List 1 Emotional Words at Endpoint</title>
        <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition measuring immediate recall of 15 emotional words; higher number of words is better recall.</description>
        <time_frame>Baseline to 6 Weeks LOCF</time_frame>
        <population>Intent to treat (ITT) population observed cases</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Affective Interference Test Immediate Recall List 1 Emotional Words at Endpoint</title>
          <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition measuring immediate recall of 15 emotional words; higher number of words is better recall.</description>
          <population>Intent to treat (ITT) population observed cases</population>
          <units>words</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="0.15"/>
                    <measurement group_id="O2" value="-0.30" spread="0.15"/>
                    <measurement group_id="O3" value="-0.06" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1836</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1374</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Affective Interference Test Immediate Recall Non-Emotional Words List 1 at Endpoint</title>
        <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This instrument measures immediate recall of 15 non-emotional words (List 1); higher number of words is better recall.</description>
        <time_frame>Baseline to 6 Weeks LOCF</time_frame>
        <population>Intent to treat (ITT) population observed cases</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Affective Interference Test Immediate Recall Non-Emotional Words List 1 at Endpoint</title>
          <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This instrument measures immediate recall of 15 non-emotional words (List 1); higher number of words is better recall.</description>
          <population>Intent to treat (ITT) population observed cases</population>
          <units>words</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.15"/>
                    <measurement group_id="O2" value="0.14" spread="0.15"/>
                    <measurement group_id="O3" value="-0.00" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9237</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3786</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Affective Interference Test, Immediate Recall, List 2 Emotional Words at Endpoint</title>
        <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This test is in Brief Assessment of Cognition and measures immediate recall of 15 emotional words (List 2); higher number of words is better recall</description>
        <time_frame>Baseline to 6 Weeks LOCF</time_frame>
        <population>Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Affective Interference Test, Immediate Recall, List 2 Emotional Words at Endpoint</title>
          <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This test is in Brief Assessment of Cognition and measures immediate recall of 15 emotional words (List 2); higher number of words is better recall</description>
          <population>Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
          <units>words</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.19"/>
                    <measurement group_id="O2" value="-0.05" spread="0.19"/>
                    <measurement group_id="O3" value="0.05" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4624</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5971</p_value>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Affective Interference Test, Immediate Recall, List 2 Non-Emotional Words at Endpoint</title>
        <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures immediate recall of 15 non-emotional words (List 2); higher number of words is better recall</description>
        <time_frame>Baseline to 6 Weeks LOCF</time_frame>
        <population>Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Affective Interference Test, Immediate Recall, List 2 Non-Emotional Words at Endpoint</title>
          <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures immediate recall of 15 non-emotional words (List 2); higher number of words is better recall</description>
          <population>Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
          <units>words</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="0.19"/>
                    <measurement group_id="O2" value="0.07" spread="0.19"/>
                    <measurement group_id="O3" value="0.13" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1378</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7665</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Affective Interference Test, Immediate Recall, List 3 Emotional Words at Endpoint</title>
        <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures immediate recall of 15 emotional words (List 3); higher number of words is better recall</description>
        <time_frame>Baseline to Week 6 LOCF</time_frame>
        <population>Intent to treat (ITT) population observed cases.Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Affective Interference Test, Immediate Recall, List 3 Emotional Words at Endpoint</title>
          <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures immediate recall of 15 emotional words (List 3); higher number of words is better recall</description>
          <population>Intent to treat (ITT) population observed cases.Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
          <units>words</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="0.21"/>
                    <measurement group_id="O2" value="-0.30" spread="0.20"/>
                    <measurement group_id="O3" value="-0.03" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4767</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2066</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Affective Interference Test, Immediate Recall, List 3 Non-Emotional Words at Endpoint</title>
        <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures immediate recall of 15 non-emotional words (List 3); higher number of words is better recall</description>
        <time_frame>Baseline to Week 6 LOCF</time_frame>
        <population>Intent to treat (ITT) population observed cases</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Affective Interference Test, Immediate Recall, List 3 Non-Emotional Words at Endpoint</title>
          <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures immediate recall of 15 non-emotional words (List 3); higher number of words is better recall</description>
          <population>Intent to treat (ITT) population observed cases</population>
          <units>words</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.19"/>
                    <measurement group_id="O2" value="-0.15" spread="0.19"/>
                    <measurement group_id="O3" value="-0.24" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1667</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6727</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Affective Interference Test, Immediate Recall, Cued-Recall Non-Emotional Words at Endpoint</title>
        <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures immediate recall (Cued) of 15 non-emotional words; higher number of words is better recall</description>
        <time_frame>Baseline to 6 Weeks LOCF</time_frame>
        <population>Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Affective Interference Test, Immediate Recall, Cued-Recall Non-Emotional Words at Endpoint</title>
          <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures immediate recall (Cued) of 15 non-emotional words; higher number of words is better recall</description>
          <population>Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
          <units>words</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.18"/>
                    <measurement group_id="O2" value="-0.01" spread="0.18"/>
                    <measurement group_id="O3" value="-0.32" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7019</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1020</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Affective Interference Test, Immediate Recall, Cued-Recall Emotional Words at Endpoint</title>
        <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures immediate recall (Cued) of 15 emotional words; higher number of words is better recall</description>
        <time_frame>Baseline to 6 Weeks LOCF</time_frame>
        <population>Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Affective Interference Test, Immediate Recall, Cued-Recall Emotional Words at Endpoint</title>
          <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures immediate recall (Cued) of 15 emotional words; higher number of words is better recall</description>
          <population>Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
          <units>words</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.20"/>
                    <measurement group_id="O2" value="-0.07" spread="0.20"/>
                    <measurement group_id="O3" value="0.08" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4749</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4491</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Digit Sequencing Task at Endpoint</title>
        <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition in which patient sequences digits from lowest to highest. Range of number of correct responses (0-28); higher numbers show better digit sequencing and greater cognition.</description>
        <time_frame>Baseline to 6 Weeks LOCF</time_frame>
        <population>Intent to treat (ITT) population observed cases</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Digit Sequencing Task at Endpoint</title>
          <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition in which patient sequences digits from lowest to highest. Range of number of correct responses (0-28); higher numbers show better digit sequencing and greater cognition.</description>
          <population>Intent to treat (ITT) population observed cases</population>
          <units>Number Correct</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="0.37"/>
                    <measurement group_id="O2" value="0.09" spread="0.37"/>
                    <measurement group_id="O3" value="0.46" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4398</p_value>
            <p_value_desc>For all efficacy analyses, no multiple comparisons adjustments were made.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3331</p_value>
            <p_value_desc>For all efficacy analyses, no multiple comparisons adjustments were made.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Token Motor Task at Endpoint</title>
        <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition in which a patient places as many of 100 tokens (2 at a time) into a container as they can within 60 seconds. The higher number of tokens placed = patient is better at motor tasks</description>
        <time_frame>Baseline to 6 Weeks LOCF</time_frame>
        <population>Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Token Motor Task at Endpoint</title>
          <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition in which a patient places as many of 100 tokens (2 at a time) into a container as they can within 60 seconds. The higher number of tokens placed = patient is better at motor tasks</description>
          <population>Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
          <units>Number of Tokens</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="1.54"/>
                    <measurement group_id="O2" value="-0.00" spread="1.53"/>
                    <measurement group_id="O3" value="2.02" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2763</p_value>
            <p_value_desc>For all efficacy analyses, no multiple comparisons adjustments were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2048</p_value>
            <p_value_desc>For all efficacy analyses, no multiple comparisons adjustments were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Verbal Fluency in Naming Categories at Endpoint</title>
        <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition.Patients are given 60 seconds to name as many words as possible within a given category. The more words named=better cognition.</description>
        <time_frame>Baseline to 6 Weeks LOCF</time_frame>
        <population>Intent to treat (ITT) population observed cases.Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Verbal Fluency in Naming Categories at Endpoint</title>
          <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition.Patients are given 60 seconds to name as many words as possible within a given category. The more words named=better cognition.</description>
          <population>Intent to treat (ITT) population observed cases.Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
          <units>Number Correct</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.58"/>
                    <measurement group_id="O2" value="-0.11" spread="0.58"/>
                    <measurement group_id="O3" value="-0.28" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4340</p_value>
            <p_value_desc>For all efficacy analyses, no multiple comparisons adjustments were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7774</p_value>
            <p_value_desc>For all efficacy analyses, no multiple comparisons adjustments were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Verbal Fluency Controlled Word Association at Endpoint</title>
        <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition. Patients given 60 seconds to generate as many words as possible that begin with a given letter; better verbal fluency = more words</description>
        <time_frame>Baseline to 6 Weeks LOCF</time_frame>
        <population>Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Verbal Fluency Controlled Word Association at Endpoint</title>
          <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition. Patients given 60 seconds to generate as many words as possible that begin with a given letter; better verbal fluency = more words</description>
          <population>Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
          <units>Number Correct</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="0.67"/>
                    <measurement group_id="O2" value="-0.15" spread="0.66"/>
                    <measurement group_id="O3" value="1.54" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5195</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0153</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Symbol Coding at Endpoint</title>
        <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition. For 90 seconds, Patient writes numerals 1-9 as matched to symbols. Range 0 to 110 with higher totals = better cognition.</description>
        <time_frame>Baseline to 6 Weeks LOCF</time_frame>
        <population>Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Symbol Coding at Endpoint</title>
          <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition. For 90 seconds, Patient writes numerals 1-9 as matched to symbols. Range 0 to 110 with higher totals = better cognition.</description>
          <population>Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
          <units>Total Correct</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" spread="1.18"/>
                    <measurement group_id="O2" value="1.07" spread="1.16"/>
                    <measurement group_id="O3" value="2.66" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2847</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1958</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Tower of London Test at Endpoint</title>
        <description>Change is observed value at each visit minus baseline value. Endpoint: LOCF endpoint among Week 1 through Week 6. Brief Assessment of Cognition: subjects asked to arrange balls in 2 pictures so they are identical and give the total number of ball movements to reach this arrangment. Range: 0-22; more correct = better cognition.</description>
        <time_frame>Baseline to 6 Weeks LOCF</time_frame>
        <population>Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tower of London Test at Endpoint</title>
          <description>Change is observed value at each visit minus baseline value. Endpoint: LOCF endpoint among Week 1 through Week 6. Brief Assessment of Cognition: subjects asked to arrange balls in 2 pictures so they are identical and give the total number of ball movements to reach this arrangment. Range: 0-22; more correct = better cognition.</description>
          <population>Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
          <units>Number Correct</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="0.41"/>
                    <measurement group_id="O2" value="0.68" spread="0.41"/>
                    <measurement group_id="O3" value="0.91" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1652</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5997</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Affective Interference Test, Delayed Recognition, Emotional Words at Endpoint</title>
        <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. Test in Brief Assessment of Cognition in which the number of correct emotional words in delayed recognition is measured. Range 0-75 with higher numbers showing better cognition.</description>
        <time_frame>Baseline to 6 Weeks LOCF</time_frame>
        <population>Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Affective Interference Test, Delayed Recognition, Emotional Words at Endpoint</title>
          <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. Test in Brief Assessment of Cognition in which the number of correct emotional words in delayed recognition is measured. Range 0-75 with higher numbers showing better cognition.</description>
          <population>Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6</population>
          <units>Words</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.22"/>
                    <measurement group_id="O2" value="0.15" spread="0.22"/>
                    <measurement group_id="O3" value="0.23" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0082</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7037</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Affective Interference Test, Delayed Recognition, Emotional Words False Alarms at Endpoint</title>
        <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. Test in Brief Assessment of Cognition which measures number of correct emotional word's false alarms (during delayed recognition). Higher number = better cognition</description>
        <time_frame>Baseline to 6 Weeks LOCF</time_frame>
        <population>Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Affective Interference Test, Delayed Recognition, Emotional Words False Alarms at Endpoint</title>
          <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. Test in Brief Assessment of Cognition which measures number of correct emotional word's false alarms (during delayed recognition). Higher number = better cognition</description>
          <population>Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
          <units>Number Correct</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.10"/>
                    <measurement group_id="O2" value="0.01" spread="0.10"/>
                    <measurement group_id="O3" value="-0.03" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2718</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7077</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Affective Interference Test, Delayed Recognition, Non-Emotional Words at Endpoint</title>
        <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures number of Non-Emotional Words (Delayed Recognition); higher number of words = better cognition</description>
        <time_frame>Baseline to Week 6 LOCF</time_frame>
        <population>Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Affective Interference Test, Delayed Recognition, Non-Emotional Words at Endpoint</title>
          <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures number of Non-Emotional Words (Delayed Recognition); higher number of words = better cognition</description>
          <population>Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
          <units>Number Correct</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="0.23"/>
                    <measurement group_id="O2" value="-0.24" spread="0.23"/>
                    <measurement group_id="O3" value="-0.02" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5057</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3654</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Affective Interference Test, Delayed Recognition, Non-Emotional Words False Alarms at Endpoint</title>
        <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures number of correct non-eEmotional word's false alarms(at delayed recognition). Higher number of words = greater cognition</description>
        <time_frame>Baseline to Week 6 LOCF</time_frame>
        <population>Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>120-160mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
          </group>
          <group group_id="O2">
            <title>40-80 mg Ziprasidone</title>
            <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects were assigned to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Affective Interference Test, Delayed Recognition, Non-Emotional Words False Alarms at Endpoint</title>
          <description>Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures number of correct non-eEmotional word's false alarms(at delayed recognition). Higher number of words = greater cognition</description>
          <population>Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6.</population>
          <units>Number Correct</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.15"/>
                    <measurement group_id="O2" value="0.19" spread="0.15"/>
                    <measurement group_id="O3" value="0.14" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6227</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Endpoint</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7737</p_value>
            <p_value_desc>For all secondary efficacy analyses, no multiple comparison adjustment were made</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model included model terms of treatment, rapid cycling, center, prior hospitalization status, as well as baseline value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>120-160mg Ziprasidone</title>
          <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day)</description>
        </group>
        <group group_id="E2">
          <title>40-80 mg Ziprasidone</title>
          <description>Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID)</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Subjects were assigned to placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (v11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7"/>
                <counts group_id="E2" subjects_affected="3"/>
                <counts group_id="E3" subjects_affected="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Hallucination, auditory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (v11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="89"/>
                <counts group_id="E2" subjects_affected="70"/>
                <counts group_id="E3" subjects_affected="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of &lt;60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), &lt;12 mo from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

